Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22

Oncogene volume 30, pages 1290–1301 (2011)Cite this article

Subjects

Abstract

Metastasis in breast cancer carries a disproportionately worse prognosis than localized primary disease. To identify microRNAs (miRNA) involved in metastasis, the expression of 254 miRNAs was measured across the following cell lines using microarray analysis: MDA-MB-231 breast cancer cells, cells that grew as a tumor in the mammary fat pad of nude mice (TMD-231), metastatic disease to the lungs (LMD-231), bone (BMD-231) and adrenal gland (ADMD-231). A brain-seeking variant of this cell line (231-BR) was used additionally in validation studies. Twenty miRNAs were upregulated and seven were downregulated in metastatic cancer cells compared with TMD-231 cells. The expression of the tumor suppressor miRNAs let-7 and miR-22 was consistently downregulated in metastatic cancer cells. These metastatic cells expressed higher levels of putative/proven miR-22 target oncogenes ERBB3, CDC25C and EVI-1. Introduction of miR-22 into cancer cells reduced the levels of ERBB3 and EVI-1 as well as phospho-AKT, an EVI-1 downstream target. The miR-22 primary transcript is located in the 5′-untranslated region of an open reading frame C17orf91, and the promoter/enhancer of C17orf91 drives miR-22 expression. We observed elevated C17orf91 expression in non-basal subtype compared with basal subtype breast cancers. In contrast, elevated expression of EVI-1 was observed in basal subtype and was associated with poor outcome in estrogen receptor-negative breast cancer patients. These results suggest that metastatic cancer cells increase specific oncogenic signaling proteins through downregulation of miRNAs. Identifying such metastasis-specific oncogenic pathways may help to manipulate tumor behavior and aid in the design of more effective targeted therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Accession codes

Accessions

Gene Expression Omnibus

References

  • Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS et al. (2004). Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. Br J Cancer 90: 853–859.

    Article  CAS  Google Scholar 

  • Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS et al. (2009). Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37: 4850–4861.

    Article  CAS  Google Scholar 

  • Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ et al. (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 8: R214.

    Article  Google Scholar 

  • Campbell MR, Amin D, Moasser MM . (2010). HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16: 1373–1383.

    Article  CAS  Google Scholar 

  • Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P et al. (2009). The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 106: 15732–15737.

    Article  CAS  Google Scholar 

  • Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43–50.

    Article  CAS  Google Scholar 

  • Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H . (2007). NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711–724.

    Article  CAS  Google Scholar 

  • Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B et al. (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207–3214.

    Article  CAS  Google Scholar 

  • Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F et al. (2009). miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4: e7181.

    Article  Google Scholar 

  • Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM . (2006). Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215–15226.

    Article  CAS  Google Scholar 

  • Friedl P, Wolf K . (2003). Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362–374.

    Article  CAS  Google Scholar 

  • Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23: 2140–2151.

    Article  CAS  Google Scholar 

  • Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M et al. (2010). EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 24: 81–88.

    Article  CAS  Google Scholar 

  • Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L et al. (2008). Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100: 1092–1103.

    Article  CAS  Google Scholar 

  • Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C et al. (2005). Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70: 149–158.

    Article  CAS  Google Scholar 

  • Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. (2010). An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123: 725–731.

    Article  Google Scholar 

  • Helbig G, Christopherson II KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD et al. (2003). NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278: 21631–21638.

    Article  CAS  Google Scholar 

  • Hoser M, Baader SL, Bosl MR, Ihmer A, Wegner M, Sock E . (2007). Prolonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia. J Neurosci 27: 5495–5505.

    Article  CAS  Google Scholar 

  • Hurst DR, Edmonds MD, Welch DR . (2009). Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495–7498.

    Article  CAS  Google Scholar 

  • Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ . (2007). A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 21: 3238–3243.

    Article  CAS  Google Scholar 

  • Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A . (2008). Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 3: e3740.

    Article  Google Scholar 

  • Inui M, Martello G, Piccolo S . (2010). MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11: 252–263.

    Article  CAS  Google Scholar 

  • Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537–549.

    Article  CAS  Google Scholar 

  • Koshiol J, Wang E, Zhao Y, Marincola F, Landi MT . (2010). Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev 19: 907–911.

    Article  CAS  Google Scholar 

  • Kumano K, Kurokawa M . (2010). The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells. J Cell Physiol 222: 282–285.

    Article  CAS  Google Scholar 

  • Lewis BP, Burge CB, Bartel DP . (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.

    Article  CAS  Google Scholar 

  • Liu Y, Chen L, Ko TC, Fields AP, Thompson EA . (2006). Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 25: 3565–3575.

    Article  CAS  Google Scholar 

  • Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Benes V et al. (2009). Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 69: 8332–8340.

    Article  CAS  Google Scholar 

  • Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK et al. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24.

    Article  Google Scholar 

  • Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550–13555.

    Article  CAS  Google Scholar 

  • Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG et al. (2010). A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24: 447–463.

    Article  CAS  Google Scholar 

  • Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA . (2009). MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293–302.

    Article  CAS  Google Scholar 

  • O'Day E, Lal A . (2010). MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201.

    Article  Google Scholar 

  • Pandey DP, Picard D . (2009). miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29: 3783–3790.

    Article  CAS  Google Scholar 

  • Ramaswamy S, Ross KN, Lander ES, Golub TR . (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49–54.

    Article  CAS  Google Scholar 

  • Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121–132.

    Article  CAS  Google Scholar 

  • Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al. (2008). The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405–5413.

    Article  CAS  Google Scholar 

  • Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437–441.

    Article  CAS  Google Scholar 

  • Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y et al. (2009). Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 28: 4364–4374.

    Article  CAS  Google Scholar 

  • Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262–272.

    Article  CAS  Google Scholar 

  • Steeg PS . (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895–904.

    Article  CAS  Google Scholar 

  • Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R . (2008). Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7: 464–473.

    Article  CAS  Google Scholar 

  • Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147–152.

    Article  CAS  Google Scholar 

  • Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC et al. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032–1046.

    Article  CAS  Google Scholar 

  • Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. (2008). Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695–1699.

    Article  CAS  Google Scholar 

  • Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671–679.

    Article  CAS  Google Scholar 

  • Wieser R . (2007). The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396: 346–357.

    Article  CAS  Google Scholar 

  • Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work is supported by Indiana University Simon Cancer Center Pilot grant and by Komen for Cure grant BCTR0601111 to HN. JBP and RMB are supported by National Institutes of Health Training Grants T32 DK07519 and T32 CA111198, respectively. HN is Marian J Morrison Professor of Breast Cancer Research.

Author information

Author notes

  1. J B Patel and H N Appaiah: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA

    J B Patel, H N Appaiah, R M Burnett, P Bhat-Nakshatri & H Nakshatri

  2. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    G Wang & Y Liu

  3. Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

    R Mehta & S Badve

  4. Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical School, Nashville, TN, USA

    M J Thomson

  5. Department of Cell and Developmental Biology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

    S Hammond

  6. Laboratory of Molecular Pharmacology, Center for Cancer Research National Cancer Institute, Bethesda, MD, USA

    P Steeg

  7. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

    H Nakshatri

Authors
  1. J B Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H N Appaiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R M Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Bhat-Nakshatri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Badve
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M J Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Hammond
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Steeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Nakshatri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Nakshatri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, J., Appaiah, H., Burnett, R. et al. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 30, 1290–1301 (2011). https://doi.org/10.1038/onc.2010.510

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.510

Keywords

This article is cited by

Search

Advanced search

Quick links